12:32 PM EST - NeonMind Biosciences Inc. : Announced today a strategic reorganization to focus on the execution of the Company's integrated drug development plan ("IDP") for its lead drug candidate targeting obesity, NEO-001. This new structure reorganizes NeonMind's business operations to focus on its core Pharmaceutical Division, and establishes resources to execute on the Company's regulatory and clinical operations strategy. This includes the establishment of a Research and Development Advisory Board and the expansion of NeonMind's regulatory team through the engagement of several key industry professionals. The reorganization will enable NeonMind to successfully execute its IDP by streamlining its corporate structure and leveraging the guidance of regulatory experts. NeonMind Biosciences Inc.
shares C.NEON are trading down 3.33 percent at $0.15.
